Management of Polycythemia Vera with High Platelet Count

Risk Stratification and Treatment

The National Comprehensive Cancer Network recommends that all patients with polycythemia vera (PV) and elevated platelets require phlebotomy to maintain hematocrit strictly below 45% plus low-dose aspirin, with cytoreductive therapy added based on thrombotic risk stratification rather than platelet count alone 1, 2
High-risk patients (age >60 years and/or prior thrombosis history) require cytoreductive therapy in addition to phlebotomy and aspirin, as recommended by the National Comprehensive Cancer Network and the Journal of Clinical Oncology 1, 3
Low-risk patients (age ≤60 years with no thrombosis history) can be managed with phlebotomy and aspirin alone, regardless of platelet elevation, according to the National Comprehensive Cancer Network and the Journal of Clinical Oncology 1, 2

Phlebotomy should maintain hematocrit <45% in all patients, as this target significantly reduces thrombotic events compared to higher targets, as reported by the Journal of Clinical Oncology 3
Low-dose aspirin (81-100 mg daily) is recommended for all patients without contraindications, as it significantly reduces cardiovascular events, according to the Journal of Clinical Oncology 3

Hydroxyurea (starting 500 mg twice daily, titrated to at least 2 g/day) is first-line cytoreductive therapy for patients >40 years old, as recommended by the Annals of Oncology and the Journal of Clinical Oncology 4, 3
Interferon-α (including pegylated formulations) is preferred for younger patients (<40 years) and women of childbearing potential due to concerns about hydroxyurea's teratogenic and potential leukemogenic effects, according to the National Comprehensive Cancer Network and the Journal of Clinical Oncology 1, 3

Extreme thrombocytosis (>1,000-1,500 × 10⁹/L) paradoxically increases bleeding risk rather than thrombotic risk due to acquired von Willebrand disease, which occurs in more than one-third of PV patients with extreme platelet elevation, as reported by the Mayo Clinic Proceedings 5, 6
Moderate thrombocytosis alone (<1,000 × 10⁹/L) is NOT an independent indication for cytoreductive therapy in low-risk patients, as studies show elevated platelet counts at diagnosis may actually be associated with lower thrombosis rates, according to the National Comprehensive Cancer Network 1

Resistance or intolerance to hydroxyurea is defined as: need for phlebotomy to maintain hematocrit <45% after 3 months of ≥2 g/day hydroxyurea, uncontrolled myeloproliferation, cytopenia, or unacceptable toxicity, as reported by the Annals of Oncology and the Journal of Clinical Oncology 4, 3

Do not initiate cytoreductive therapy based solely on platelet count in otherwise low-risk patients with well-controlled cardiovascular risk factors, as recommended by the Journal of Clinical Oncology 3
Do not target platelet counts aggressively in patients with extreme thrombocytosis and bleeding - the priority is cytoreduction to normalize counts and reverse acquired von Willebrand disease, not antiplatelet therapy, according to the Mayo Clinic Proceedings 5, 6
Do not use hematocrit targets >45% - the CYTO-PV trial definitively established superiority of <45% target over higher targets for preventing thrombosis, as reported by the Annals of Oncology 4